- Home
- CRT vs SAVA Comparison
CRT vs SAVA Comparison
Compare CRT & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- SAVA
- Stock Information
- Founded
- CRT 1991
- SAVA 1998
- Country
- CRT United States
- SAVA United States
- Employees
- CRT N/A
- SAVA N/A
- Industry
- CRT Oil & Gas Production
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- SAVA Health Care
- Exchange
- CRT Nasdaq
- SAVA Nasdaq
- Market Cap
- CRT 65.1M
- SAVA 70.5M
- IPO Year
- CRT 1992
- SAVA N/A
- Fundamental
- Price
- CRT $9.80
- SAVA $2.10
- Analyst Decision
- CRT
- SAVA Buy
- Analyst Count
- CRT 0
- SAVA 3
- Target Price
- CRT N/A
- SAVA $54.50
- AVG Volume (30 Days)
- CRT 25.1K
- SAVA 1.3M
- Earning Date
- CRT 01-01-0001
- SAVA 05-08-2025
- Dividend Yield
- CRT 9.16%
- SAVA N/A
- EPS Growth
- CRT N/A
- SAVA N/A
- EPS
- CRT 0.99
- SAVA N/A
- Revenue
- CRT $6,834,116.00
- SAVA N/A
- Revenue This Year
- CRT N/A
- SAVA N/A
- Revenue Next Year
- CRT N/A
- SAVA N/A
- P/E Ratio
- CRT $10.02
- SAVA N/A
- Revenue Growth
- CRT N/A
- SAVA N/A
- 52 Week Low
- CRT $8.88
- SAVA $1.15
- 52 Week High
- CRT $14.40
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CRT 41.73
- SAVA 58.24
- Support Level
- CRT $9.93
- SAVA $1.96
- Resistance Level
- CRT $10.70
- SAVA $2.22
- Average True Range (ATR)
- CRT 0.24
- SAVA 0.15
- MACD
- CRT 0.00
- SAVA 0.00
- Stochastic Oscillator
- CRT 10.98
- SAVA 51.09
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.